From: John Morris

Sent: 10 March 2006 15:12

To: 'Alana Miller'

Subject: Interferon...mild hepatitis C -- part review of existing guidance no. 75. Comments on

ACD by Haemophilia Society

Alana

The Haemophilia Society UK commends the Appraisal Committee on its findings expressed in this ACD and warmly accepts all the conclusions and guidance. Extension of treatment to those with mild hepatitis C and the importance of counseling to assist decision-making were important goals for us.

A delay in the full review date to from November 2006 is entirely sensible. We are interested in refinements to the interferon-treatment regimes, particularly if it is possible to reduce the duration of therapy without impacting on predicting success rates, but defer to clinical experts for guidance on whether November 2008 is a suitable point in time for the next full review. Should any new treatments for chronic hepatitis C be licensed, we would also urge NICE to begin a new appraisal process for these in a timely fashion.

With best regards
John Morris
John Morris Services Development Manager Direct line: Email:
Delivered via MessageLabs